2021 Revenues ($USD) : $8,899,380,918
2021 Revenues (foreign currencies) : JP¥977,508,000,000
2021 R&D spend : $1,985,196,650
2021 Number of Employees : na
Fiscal Year End : 12/31/2021
Leader : CEO Tatsuo Higuchi

Priority areas for Otsuka’s pharma business include psychiatry, neurology and oncology. Revenue grew 2.3% in 2021. New product groups — including INQOVI to treat adults with myelodysplastic syndromes, including chronic myelomonocytic leukemia — made up for the impact of the expiration of co-promotion agreements. —CN